Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Thyroid Cancer

Trial Information

Anaplastic Thyroid Cancer Research Study

Study Title:
Phase 1/2 Study of CS-7017, an Oral PPAR? Agonist, in Combination with Paclitaxel in Subjects with Advanced Anaplastic Thyroid Cancer.

Study Design:
This is an open-label, multicenter study for first-line treatment of advanced anaplastic thyroid cancer (ATC). It includes a dose escalation portion (Phase 1) in which the recommended Phase 2 dose of CS-7017 and paclitaxel will be determined. In Phase 2 the efficacy and safety of the combination at the determined dose level will be evaluated.

During both portions of the study, there will be a 1 week run in segment with CS 7017 administered alone. CS 7017 will be administered by mouth twice a day. Paclitaxel will be administered as an intravenous infusion over 3 hours once every 3 weeks. Treatment will continue until disease progression, unacceptable toxicity, or consent withdrawal. After discontinuation from the study, the subject will be contacted at 3 month intervals to obtain information about subsequent treatment(s) and survival status.

Eligibility Overview:
To be eligible for the Phase I portion of this study, a patient must have advanced ATC with lesion(s) accessible for repeated biopsy. The potential subject must be at least 18 years of age and have adequate organ and bone marrow function. The patient cannot have a medical history of diabetes that requires treatment with insulin or oral agents and cannot have significant lung or heart disease. Pregnant and breast feeding women are not allowed onto this study.

Further Information:
Ten study sites in the US are participating in this study. For further information about this study, you and/or your health care provider may contact the study center manager, Shirley Deasy (ICON Clinical Research) at 919 554-0741, shirley.deasy@iconplc.com or Brittany Hines at 720-848-0634 Brittany.Hines@ucdenver.edu.

Brittany Hines
University of Colorado Cancer Center
1665 N. Ursula St. - Room 3200 / Box 6510
Aurora, CO 80045
Phone: 720-848-0634
EMail: Brittany.Hines@ucdenver.edu

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.